SCHEMBL5136254

SCHEMBL5136254

CCCCN(Cc1ccc(OC)cc1)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
BCL2L2 Q92843 1/20 0.38
TSHR P16473 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ATP4A P20648 2/20 0.37
ATP4B P51164 2/20 0.37
CASR P41180 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.36
SMPD1 P17405 1/20 0.36
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
BCHE P06276 3/20 0.36
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138077 0.92 C5AR1 (0.39) C5AR1BCL2L2TSHRKDM4EALDH1A1
SCHEMBL5136568 0.92 CRHR1 (0.38) C5AR1BCL2L2TSHRLMNAATP4A
SCHEMBL5137164 0.91 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5135871 0.90 ATP4A (0.44) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136086 0.88 C5AR1 (0.41) C5AR1BCL2L2KDM4EGAACASR
SCHEMBL5134684 0.88 C5AR1 (0.41) C5AR1BCL2L2TSHRKDM4EGAA
SCHEMBL5075063 0.88 TP53 (0.42) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136763 0.87 KDM4E (0.43) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136000 0.87 ATP4A (0.42) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136839 0.87 C5AR1 (0.42) C5AR1BCL2L2TSHRKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed